Zacks Investment Research Downgrades Chugai Pharmaceutical (OTCMKTS:CHGCY) to Hold

Zacks Investment Research lowered shares of Chugai Pharmaceutical (OTCMKTS:CHGCYGet Rating) from a buy rating to a hold rating in a report issued on Tuesday morning, Zacks.com reports.

According to Zacks, “CHUGAI PHARMACEUTICAL CO. LTD. is mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products for treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. CHUGAI PHARMACEUTICAL CO. LTD. is based in Tokyo, Japan. “

Separately, The Goldman Sachs Group upgraded Chugai Pharmaceutical from a neutral rating to a buy rating in a report on Thursday, January 13th.

Shares of Chugai Pharmaceutical stock opened at $13.83 on Tuesday. Chugai Pharmaceutical has a 1 year low of $13.47 and a 1 year high of $21.30. The business has a 50-day moving average of $15.97 and a two-hundred day moving average of $16.60.

Chugai Pharmaceutical Company Profile (Get Rating)

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng.

Recommended Stories

Get a free copy of the Zacks research report on Chugai Pharmaceutical (CHGCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.